|
Glizigen® and Oncoxin®-Viusid® in cervical intraepithelial lesions of adult women. Phase II |
09/05/2018 |
CATALYSIS |
|
HEBERBIOVAC HB vaccine to reference material. |
30/04/2017 |
CIGB |
|
HEBERFERON in renal cell carcinoma |
05/01/2017 |
CIGB |
|
HeberNasvac® Phase IV in Chronic Hepatitis B |
03/08/2018 |
CIGB |
|
Her1 vaccine in metastatic colon and prostate cancer |
16/08/2023 |
CIM |
|
Homeostec for chronic arthritis |
15/08/2017 |
SSA |
|
INJURE Study |
2011-07-11 |
CIGB |
|
Interferon Combination in basal cell carcinoma (InCarbacel-V study) |
2013-02-01 |
CIGB |
|
Intravenous CIGB-128-A in patients with brain tumors (BRATINC Study) |
2013-01-17 |
CIGB |
|
iorEPOCIM-Stroke-Phase I |
2012-09-17 |
CIMAB |
|
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
18/06/2021 |
CIM |
|
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |
08/10/2015 |
CIM |
|
Itolizumab for Relapsing Remitting Multiple Sclerosis |
22/05/2015 |
CIM |
|
Itolizumab Safety and Efficacy Study in Covid 19 |
26/03/2021 |
CIM |
|
Itolizumab-Plasmapheresis in patients with COVID-19 |
30/06/2021 |
CIM |
|
Jusvinza in rheumatoid arthritis |
20/04/2022 |
CIGB |
|
Jusvinza in Severe Patients with Acquired Community Pneumonia |
14/10/2022 |
CIGB |
|
Kardioli® nutritional supplement versus placebo in patients with chronic heart failure. Phase II. |
03/03/2023 |
CATALYSIS |
|
Lithium Carbonate-COVID-19- mild and moderate -Exploratory / Phase II |
05/08/2021 |
ICBPGirón |
|
MAMBISA Study |
26/11/2020 |
CIGB |
